Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Notification Protocol for IPC Failures – V 2.0

Posted on By

Elixir Department: SOP for Notification Protocol for IPC Failures – V 2.0

Standard Operating Procedure for Notification Protocol for IPC Failures in Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/209/2025
Supersedes SOP/ELX/209/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To define the procedure for immediate and structured notification in the event of In-Process Control (IPC) test failures during the manufacturing of elixirs. This ensures timely action, traceability, and regulatory compliance.

2. Scope

This SOP applies to all IPC failures observed during elixir manufacturing, including physical, chemical, and microbiological test results that fall outside predefined specifications or control limits.

3. Responsibilities

  • QC Analyst:
    • Identify, document, and immediately report IPC test failures to designated personnel.
  • Production Supervisor:
    • Halt the process upon notification and assist in sample re-testing and batch segregation.
  • QA Officer:
    • Initiate deviation report and conduct impact assessment on product quality.
See also  Elixir Department: SOP for Dispensing Solvents and Vehicles - V 2.0

4. Accountability

The QA Head is accountable for reviewing IPC failures and authorizing further action. The QC Head ensures appropriate documentation and investigation initiation.

5. Procedure

5.1

Identification of IPC Failure
  1. If a test result deviates from the defined specification in the Batch Manufacturing Record (BMR) or product standard:
    • Flag the result as IPC failure.
    • Repeat the test once using the same sample to confirm the observation.

5.2 Immediate Notification

  1. Notify the following personnel verbally and via email or documented log entry within 15 minutes:
    • Production Supervisor
    • QA Officer
    • QC Head
  2. Document the initial failure in the IPC Failure Notification Form (Annexure-1).

5.3 Action Upon Notification

  1. Production must:
    • Pause the batch process immediately.
    • Quarantine the batch and affected materials.
  2. QA must:
    • Review IPC results and start a preliminary investigation.
    • Decide on next steps: retesting, resampling, or deviation initiation.

5.4 Investigation and Documentation

  1. Complete a Deviation Form and assign a unique deviation number.
  2. Include:
    • Date and time of failure
    • Test parameter and method
    • Batch number and product details
    • Initial result and retest result
    • Impact assessment and immediate actions
  3. Attach this documentation to the BMR.

5.5 Resolution and Final Disposition

  1. Based on investigation outcome, QA decides:
    • Reprocessing
    • Rejection
    • Batch continuation (with justification)
  2. Communicate final disposition in writing to all stakeholders.

6. Abbreviations

  • IPC: In-Process Control
  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • QC: Quality Control
  • BMR: Batch Manufacturing Record

7. Documents

  1. IPC Failure Notification Form (Annexure-1)
  2. Deviation Report Form
  3. Batch Manufacturing Record (BMR)

8. References

  • 21 CFR Part 211.192 – Production Record Review
  • ICH Q10 – Pharmaceutical Quality System
  • WHO TRS 986 – GMP Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: IPC Failure Notification Form

Date & Time Batch No. Test Parameter Result Specification Notified To Initial Action
11/04/2025, 10:30 AM ELX-0425-027 pH 8.2 6.5 – 7.5 Sunita Reddy (QA) Process Paused

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial Release New SOP QA Head
11/04/2025 2.0 Included mandatory response timelines and escalation list Regulatory Alignment QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Common Pitfalls During SOP Updates and How to Avoid Them
Next Post: Analytical Method Development: SOP for API Distribution Analysis in Blend – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version